2025年10月28日，由艾森药业自主研发、具有全球知识产权的1类创新药"奥格特韦钠"获得国家药品监 督管理局签发的《药品注册证书》，成为衢州市历史上首个、浙江省该年度第三个1类创新药。该药是 全球首个针对新型冠状病毒感染治疗的双靶点抑制剂，拥有全球知识产权，标志着衢州市生物医药原始 创新能力实现跃迁。 "这几天都会加班加点生产，预计春节前将生产出20万粒奥格特韦钠胶囊，价格较进口药降低60%以 上。"徐万红说，相较于同类产品，奥格特韦钠胶囊通过同时抑制3CL蛋白酶和组织蛋白酶L，实现 了"阻断病毒入侵+抑制病毒复制"的双重作用，大幅降低了药物相互作用带来的潜在风险，尤其适合伴 有多种基础疾病的患者使用。 新药的快速获批与量产，离不开地方政府的精准帮扶。我市市场监管部门建立"全链条指导+全要素对 接"服务体系，30余次对接国家、省药品监督管理部门，为企业提供精准帮扶，助推新药加速上市。智 造新城高新企业社区服务中心全程跟进项目申报进度，针对企业临床试验、试产取证中的资金周转需 求，协调金融机构上门对接服务，助力企业顺利完成试产验收。 （来源：衢州日报） 转自：衢州日报 本报讯 （记者 邓亮 报道组 周毅辉） ...

Core Insights - The Chinese innovative pharmaceutical industry is experiencing significant transformation, marked by substantial licensing deals and a shift towards global leadership in quality over quantity [2][3][6] - The total amount of License-out upfront payments has surpassed that of the primary market for the first time, indicating a shift in funding dynamics within the industry [13][31] - Despite the growth, there are underlying challenges such as a lack of clinical development capabilities and the undervaluation of early-stage pipelines, leading to a phenomenon of "selling seedlings at a discount" [16][20][24] Group 1: Industry Growth and Transactions - In 2025, the total amount of License-out transactions in China is expected to exceed that of the U.S. by 3.2 times, reflecting a rapid acceleration in drug approvals and a surge in innovative drug development [3][6] - The total amount of BD transactions in the Chinese pharmaceutical sector has surpassed $100 billion, with a significant increase in both the number of deals and transaction values [8][11] - Major transactions include a $125 billion collaboration between Hengrui Medicine and GSK, a $114 billion partnership between Innovent Biologics and Takeda, and a $61.5 billion deal between 3SBio and Pfizer, positioning these deals among the largest in global innovative drug licensing [9][10] Group 2: Challenges and Market Dynamics - The industry faces a stark divide, with leading companies achieving profitability while smaller biotech firms struggle with funding and development risks, leading to a survival of the fittest scenario [28][31] - The proportion of License-out transactions for late-stage clinical projects has only slightly increased, indicating ongoing challenges in clinical development capabilities [16][20] - The gap in clinical trial design and execution between Chinese companies and multinational corporations (MNCs) remains significant, impacting the ability of domestic firms to retain control over late-stage assets [19][21][24] Group 3: Financial Performance and Market Reactions - Innovative drug companies in China reported a revenue increase of 22.1% year-on-year in the first three quarters of 2025, with a notable reduction in net losses [28][31] - The market is becoming more discerning, focusing on clinical value and commercialization potential rather than short-term trading excitement, leading to a more cautious approach to BD transactions [32][33] - The capital market's response to BD transactions has been mixed, with significant deals not necessarily translating into sustained stock price increases, highlighting the need for long-term value realization [32][33]